Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, December 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94.
• On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $86.23, for a total value of $370,961.46.

Palvella Therapeutics Trading Down 7.4%

PVLA stock opened at $85.30 on Friday. Palvella Therapeutics, Inc. has a 1-year low of $12.10 and a 1-year high of $114.69. The business’s 50 day moving average is $97.37 and its 200-day moving average is $70.38. The firm has a market cap of $1.01 billion, a P/E ratio of -32.43 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). Sell-side analysts forecast that Palvella Therapeutics, Inc. will post -3.69 EPS for the current year.

Analyst Upgrades and Downgrades

PVLA has been the topic of several analyst reports. Cantor Fitzgerald upped their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Canaccord Genuity Group boosted their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Stifel Nicolaus raised their price objective on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, November 24th. Finally, TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $158.69.

Hedge Funds Weigh In On Palvella Therapeutics

A number of large investors have recently modified their holdings of PVLA. First Light Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the third quarter valued at approximately $33,949,000. Federated Hermes Inc. acquired a new position in Palvella Therapeutics during the 3rd quarter worth $21,255,000. Vanguard Group Inc. lifted its holdings in Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after buying an additional 330,847 shares in the last quarter. Millennium Management LLC bought a new position in Palvella Therapeutics in the 1st quarter valued at $7,553,000. Finally, Fred Alger Management LLC boosted its position in Palvella Therapeutics by 1,279.1% in the 3rd quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock valued at $11,707,000 after buying an additional 173,209 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.